Impact of Renin-Angiotensin-Aldosterone-System Inhibition on Advanced Chronic Kidney Disease progression – a Retrospective Observational Study

Impact of Renin-Angiotensin-Aldosterone-System Inhibition on Advanced Chronic Kidney Disease progression – a Retrospective Observational Study - RAAS AdvaCKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034706

Enrollment

6000

Registered

2024-07-18

Start date

2024-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18.4

Interventions

Group 1: Retrospective analysis of patients with advanced chronisch kidney disease (CKD). Investigation whether therapeutic renin-angiotensin-aldosterone system (RAAS) inhibition leads to modulation o

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients treated at the University of Freiburg Medical Center - Treated between 01/01/2001 – 12/31/2024 - = 2 serum-creatinine values - eGFR <60 ml/miin/1.73m2

Exclusion criteria

Exclusion criteria: - hemo- or peritoneal dialysis - kidney transplantation

Design outcomes

Primary

Measure	Time frame
Annual decline in eGFR until primary endpoint (end-stage renal disease (eGFR <15 ml/min/1.73m2) is reached in patients with eGFR of 15 - 30 ml/min/1.73 m2 at baseline	—

Secondary

Measure	Time frame
Annual decline in eGFR until secondary endpoint (eGFR <30 ml/min/1.73m2) is reached in patients with eGFR of 31 -601ml/min/1.73 m2 at baseline	—

Countries

Germany

Contacts

Public ContactLukas Westermann

Universitätsklinikum Freiburg

lukas.westermann@uniklinik-freiburg.de0761 270 63056

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026